Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.

Gynecologic oncology - 1 Nov 2022

Berger Amnon A, Kawaler Emily A, Dao Fanny, Misirlioglu Selim, Fernandez Ernesto Arostegui, Olvera Narciso, Van Oudenhove Elke, DeLair Deborah, Levine Douglas A

Abstract excerpt

OBJECTIVE: Treatment options and associated biomarkers for advanced and recurrent disease are limited. Endometrial cancers (ECs) with CTNNB1 exon 3 mutations appear to have preferential response to bevacizumab, an anti-angiogenesis treatment, though the mechanism of action is unknown. We aim to identify mediators of bevacizumab-responsive endometrial cancers. METHODS: We analyzed RNA expression from TCGA and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Endometrial Neoplasms

Share to Matrix Metalloproteinase 7

Share to Mutation

Share to Neovascularization, Pathologic

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 36150916
DOI: 10.1016/j.ygyno.2022.09.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.PMID 36150916Read ↗

Mechanisms of mutant β-catenin in endometrial cancer progressionSemantic proximity Read ↗

CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomasSemantic proximity Read ↗

Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.Semantic proximity Read ↗

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.Semantic proximity Read ↗

Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid CarcinomaSemantic proximity Read ↗

CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.Semantic proximity Read ↗

Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles.Semantic proximity Read ↗

CTNNB1 mutations and beta-catenin expression in endometrial carcinomas.Semantic proximity Read ↗

The Role of CTNNB1 in Endometrial Cancer.Semantic proximity Read ↗

Harnessing AI to Reveal CTNNB1’s Central Role in Breast Cancer Progression and Drug DiscoverySemantic proximity Read ↗

Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial CancerSemantic proximity Read ↗

CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.